세푸록심

항생제 - 2세대 세팔로스포린Highly Important

세푸록심은 경구용(악세틸) 및 주사용(나트륨) 제제로 제공되는 반합성 **2세대 세팔로스포린계** 항생제입니다. * **항균 스펙트럼**: 1세대 세팔로스포린(예: 세팔렉신)과 비교하여 특정 **그람 음성 병원균**(예: 대장균, 폐렴막대균, 살모넬라, 엔테로박터)에 대해 강화된 활성을 제공하며, 많은 그람 양성균에 대해서도 좋은 효능을 유지합니다. * **임상적 유용성**: 소동물 임상에서 1세대 세팔로스포린에 내성이 있는 감염을 치료하거나, **수술 예방**을 위해 더 넓은 그람 음성균 커버리지가 필요할 때, 또는 **높은 중추신경계(CNS) 농도**가 요구될 때(수막 염증 시 통과 가능) 특히 유용합니다. * **제한 사항**: 메티실린 내성 포도상구균(MRSA/MRSP), 녹농균, 세라티아 또는 장구균에는 효과가 없습니다.

작용 기전: Cefuroxime is a **bactericidal** time-dependent antibiotic. It binds to specific **penicillin-binding proteins (PBPs)** located inside the bacterial cell wall → inhibits the third and final stage of bacterial cell wall synthesis (peptidoglycan cross-linking) → weakens the cell wall → leads to **cell lysis and death** due to osmotic pressure. *Clinical Pearl*: Like other beta-lactams, its efficacy depends on the amount of time the drug concentration remains above the Minimum Inhibitory Concentration (MIC) at the site of infection.

동물 종별 용량

Dogs

Soft tissue infections · 10 mg/kg PO q12h · PO · q12h · 10 days · Extrapolated from human dosages.
Systemic infections · 15 mg/kg IV q8h · IV · q8h · Extrapolated from human dosages.
Meningitis · 30 mg/kg IV q8h · IV · q8h · Extrapolated from human dosages.
Surgery prophylaxis · 20 mg/kg IV 30 minutes prior to surgery and every 2 hours during surgery. · IV · 30 mins prior and q2h during · Perioperative
Surgical prophylaxis · 20 mg/kg · IV · 30 min prior to surgery and then repeat q1.5-3h during surgery · Perioperative · Administer slowly over 5 min
Susceptible infections · 10-30 mg/kg · IV · q8-12h · As directed

Cats

Surgical prophylaxis · 20 mg/kg · IV · 30 min prior to surgery and then repeat q1.5-3h during surgery · Perioperative · Administer slowly over 5 min
Susceptible infections · 10-30 mg/kg · IV · q8-12h · As directed

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

POIVIM

금기

Known hypersensitivity to cefuroxime or other cephalosporins

이상반응

Inappetence
Vomiting
Diarrhea
Injection site inflammation (IV use)
Eosinophilia
Hypersensitivity reactions (including anaphylaxis)
Neurologic effects (hearing loss, seizures - rare)
Pseudomembranous colitis (rare)
Serious dermatologic reactions (TEN, Stevens-Johnson syndrome - rare)
Hematologic effects (pancytopenia, thrombocytopenia - rare)
Interstitial nephritis (rare)

약물 상호작용

Aminoglycosides · Potential for increased risk of nephrotoxicity; monitor renal function. However, may have synergistic or additive actions against some gram-negative bacteria (Enterobacteriaceae). · minor
Furosemide · Possible increased risk of nephrotoxicity. · moderate
Torsemide · Possible increased risk of nephrotoxicity.
Probenecid · Reduced renal excretion of cephalosporins, potentially increasing serum levels.
Oxytetracycline · Bacteriostatic agents may antagonize the bactericidal activity of cefuroxime. · moderate
Erythromycin · Bacteriostatic agents may antagonize the bactericidal activity of cefuroxime. · moderate
Amphotericin B · Increased risk of nephrotoxicity; monitor renal function. · major

모니터링

Clinical efficacy (resolution of infection signs)
Renal function in patients with pre-existing renal insufficiency
Gastrointestinal tolerance

과용량

Cefuroxime has a wide margin of safety. Beagles receiving daily dosages up to 1600 mg/kg/day orally tolerated the drug well, with only minor vomiting, slight weight gain suppression, and minor hematologic changes at the highest doses. In humans, massive overdoses have caused **cerebral irritation and seizures**. If severe toxicity occurs, plasma levels can be reduced via hemodialysis or peritoneal dialysis. Treatment is largely supportive.

VetSheet 약물 레퍼런스는 면허 수의 전문가를 위한 임상 의사결정 보조 도구이며, 전문적 판단이나 제조사의 최신 라벨을 대신하지 않습니다.